UPDATE: Bank of America Downgrades Idenix Pharmaceuticals to Underperform on Unfavorable Patent Ruling
March 25, 2013 at 14:01 PM EDT
In a report published Monday, Bank of America analyst Rachel McMinn downgraded the rating on Idenix Pharmaceuticals (NASDAQ: IDIX ) from Neutral to Underperform, and lowered the price target from $7.00 to $3.00. In the report, McMinn noted, “IDIX announced that US patent office determined IDIX to be the ‘junior
